AirSculpt Technologies
AirSculpt Technologies' revenue fell 15.8% to $152 million in fiscal 2025. Its operating margin was −7.6%, down from −0.9% a year earlier. Free cash flow was $1 million. The diluted share count rose 4.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What AirSculpt Technologies does
AirSculpt offers a body contouring procedure that removes fat and tightens skin without needles, scalpels, stitches or general anesthesia, according to the company. It also offers fat transfer procedures that use the patient's own fat, and treatments for skin laxity and cellulite. Procedures are done only at its own offices.
Patients pay for the procedures. The company performed 11,852 body contouring procedures in 2025. It markets mainly through its website, social media, celebrity and influencer endorsements and word-of-mouth referrals, and it shows before-and-after photos.
As of March 31, 2026 it ran 31 centers across 20 U.S. states and Canada. Its centers work with affiliated professional associations that employ the surgeons.
Its biggest risks, as it describes them
- Harm to the AirSculpt brand through changing tastes or bad publicity.
- Depending on a single procedure whose market acceptance may not grow.
- Too few patients, or patients unhappy with results.
- Limited supply of the surgeons and licensed staff it needs.
- Relying on one third-party manufacturer for key parts of its tools.
Income statement
AirSculpt Technologies lost money in fiscal 2025: a net loss of $12 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 25 | 10 | 10 | 8 | 8 |
| Debt incl. finance leases | 83 | 84 | 72 | 70 | 56 |
| Net debt (negative means net cash) | 57 | 74 | 61 | 62 | 48 |
| Net debt to EBITDA | 2.6x | 21.0x | 3.1x | 6.0x | 39.0x |
| Debt to equity | 1.0x | 1.2x | 0.9x | 0.9x | 0.6x |
| Interest coverage | 3.2x | −0.7x | 1.5x | −0.2x | −1.9x |
| Current ratio | 1.8x | 0.8x | 0.8x | 0.6x | 0.6x |
| Quick ratio | 1.8x | 0.8x | 0.8x | 0.6x | 0.6x |
Cash flow
Projections
Project AirSculpt Technologies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What AirSculpt Technologies says to expect
- Full year 2026: revenue
The Company is reducing its full-year 2026 revenue and Adjusted EBITDA guidance as follows: • Revenue in the range of approximately $144 million to $146 million, compared to the previous range of $151 million to $157 million; and
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $2.0 million of AirSculpt Technologies shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 17, 2026 | Jorey Chernett10% owner | Bought | 40,000 | $2.54 | $101,600 | Form 4 |
| Apr 14, 2026 | Jorey Chernett10% owner | Bought | 20,000 | $2.60 | $52,000 | Form 4 |
| Apr 7, 2026 | Jorey Chernett10% owner | Bought | 60,000 | $2.93 | $175,800 | Form 4 |
| Apr 3, 2026 | Jorey Chernett10% owner | Bought | 90,000 | $2.82 | $253,800 | Form 4 |
| Mar 23, 2026 | Jorey Chernett10% owner | Bought | 50,000 | $2.91 | $145,500 | Form 4 |
| Mar 20, 2026 | Jorey Chernett10% owner | Bought | 40,000 | $2.77 | $110,800 | Form 4 |
| Mar 19, 2026 | Jorey Chernett10% owner | Bought | 77,702 | $2.64 | $205,133 | Form 4 |
| Mar 17, 2026 | Jorey Chernett10% owner | Bought | 83,000 | $2.56 | $212,480 | Form 4 |
| Mar 16, 2026 | Jorey Chernett10% owner | Bought | 105,848 | $2.43 | $257,211 | Form 4 |
| Mar 11, 2026 | Jorey Chernett10% owner | Bought | 88,000 | $2.15 | $189,200 | Form 4 |
| Mar 6, 2026 | Jorey Chernett10% owner | Bought | 45,600 | $2.00 | $91,200 | Form 4 |
| Mar 4, 2026 | Jorey Chernett10% owner | Bought | 30,000 | $1.87 | $56,100 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 8 | 3 of 8 | 3 of 8 |
| Rule of 40 | 23.2% | −9.4% | −15.4% |
| Altman Z'' | 0.59 | −0.25 | −0.63 |
| Accruals ratio | −13.9% | −9.3% | −7.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | 6 of 8 | 3 of 8 | 3 of 8 |
Compare
Put AirSculpt Technologies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| AirSculpt Technologies | FY25 | −15.8% | −7.6% | 0.5% | −6.6% | 39.0x | 3 | |
| Grail | FY25 | 17.2% | −382.0% | −203.8% | — | — | — | Compare |
| SBC Medical Group | FY25 | −15.5% | 38.9% | 13.4% | 38.4% | −1.7x | 4 | Compare |
| Ridgetech | FY26 | 10.2% | −1.4% | −1.1% | — | — | — | Compare |
| biote | FY25 | −2.5% | 18.5% | 15.7% | — | 2.0x | 5 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 41 | 63 | 133 | 169 | 196 | 180 | 152 |
| Revenue growth | — | 52.2% | 112.4% | 26.6% | 16.1% | −8.0% | −15.8% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — | — |
| Operating income | 1 | 10 | 16 | −4 | 10 | −2 | −12 |
| Net income | −2 | 8 | 11 | −15 | −4 | −8 | −12 |
| Diluted EPS (US$) | — | — | −0.01 | −0.26 | −0.08 | −0.14 | −0.19 |
| Diluted shares (millions) | — | — | 56 | 56 | 57 | 58 | 60 |
| Cash flow | |||||||
| Cash from operations | 5 | 14 | 27 | 24 | 24 | 11 | 3 |
| Capital expenditure | 4 | 4 | 7 | 13 | 10 | 14 | 2 |
| Free cash flow | 0 | 10 | 20 | 12 | 14 | −3 | 1 |
| Dividends paid | 0 | 0 | 0 | 23 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 7 | 30 | 18 | 4 | 2 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 5 | 10 | 25 | 10 | 10 | 8 | 8 |
| Debt incl. finance leases | — | 32 | 83 | 84 | 72 | 70 | 56 |
| Total assets | — | 180 | 201 | 201 | 204 | 213 | 187 |
| Total liabilities | — | 56 | 117 | 130 | 120 | 135 | 100 |
| Shareholders' equity | — | — | 84 | 71 | 83 | 78 | 88 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | 1.6% | 16.0% | 11.8% | −2.7% | 5.0% | −0.9% | −7.6% |
| Net margin | −5.4% | 12.1% | 7.9% | −8.7% | −2.2% | −4.5% | −7.7% |
| Free cash flow margin | 1.2% | 16.4% | 14.6% | 6.8% | 7.2% | −1.5% | 0.5% |
| Rule of 40 (growth + FCF margin) | — | 68.6% | 127.0% | 33.4% | 23.2% | −9.4% | −15.4% |
| Return on capital | — | — | — | −2.5% | 3.4% | −0.9% | −6.6% |
| Return on equity | — | — | — | −19.0% | −5.5% | −10.0% | −14.1% |
| Return on assets | — | — | 5.5% | −7.3% | −2.1% | −3.9% | −5.8% |
| Net debt to EBITDA | — | 1.4x | 2.6x | 21.0x | 3.1x | 6.0x | 39.0x |